PROJECT SUMIVIARY (See instructions): Core C will provide support for research sample collection for BMT patients and ensure proper and consistent quality control regarding the collection, processing, archiving and distribution of samples. Core C will also ensure quality control of the clinical status and endpoints of individuals whose samples are collected and analyzed. In addition, Core C will continue to support exploratory proteomic profiling of clinical research samples from allogeneic BMT patients. During this last cycle. Core C has been instrumental in the development and validation of a four biomarker panel of GVHD. The services provided by Core C will include the following: 1. To collect, process, store, and distribute patient derived research samples 2. To collect data for, quality control, and maintain the integrated comprehensive patient database 3. To provide cutting edge proteomic analysis technology

Public Health Relevance

Allogeneic hematopoietic stem cell transplantation is a potentially curative therapy for many malignant diseases whose applicability has been impeded by the development of its most serious complication, GVHD. Strategies that mitigate GVHD will allow for better harnessing of this effective therapeutic modality to treat many patients with hematological cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
7P01CA039542-27
Application #
8725949
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
27
Fiscal Year
2014
Total Cost
$177,805
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Glick, Gary D; Rossignol, Rodrigue; Lyssiotis, Costas A et al. (2014) Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther 351:298-307
Choi, Sung Won; Braun, Thomas; Chang, Lawrence et al. (2014) Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 15:87-95
Vander Lugt, Mark T; Braun, Thomas M; Hanash, Samir et al. (2013) ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 369:529-39
Harris, Andrew C; Ferrara, James L M; Levine, John E (2013) Advances in predicting acute GVHD. Br J Haematol 160:288-302
MacDonald, Kelli P; Shlomchik, Warren D; Reddy, Pavan (2013) Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant 19:S10-4
Byersdorfer, Craig A; Tkachev, Victor; Opipari, Anthony W et al. (2013) Effector T cells require fatty acid metabolism during murine graft-versus-host disease. Blood 122:3230-7
Levine, John E; Huber, Elisabeth; Hammer, Suntrea T G et al. (2013) Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood 122:1505-9
Harris, Andrew C; Kitko, Carrie L; Couriel, Daniel R et al. (2013) Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 98:179-84
Brown, J R; Kim, H T; Armand, P et al. (2013) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27:362-9
Paczesny, Sophie (2013) Discovery and validation of graft-versus-host disease biomarkers. Blood 121:585-94

Showing the most recent 10 out of 197 publications